Benzinga | Aug 26, 2021 04:11PM EDT

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs

* Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody(tm) technology to create new immune-stimulating antibody conjugates (ISACs)

* Innovent will pay Bolt an upfront payment and fund development through clinical proof of concept

* Innovent has rights to all programs in Greater China, and both parties have options to participate in full development and commercialization for various regions